livanova plc - LIVN

LIVN

Close Chg Chg %
73.72 -1.36 -1.84%

Closed Market

72.36

-1.36 (1.84%)

Volume: 412.88K

Last Updated:

Jun 5, 2026, 4:00 PM EDT

Company Overview: livanova plc - LIVN

LIVN Key Data

Open

$73.64

Day Range

72.07 - 74.48

52 Week Range

41.02 - 75.82

Market Cap

$4.05B

Shares Outstanding

54.93M

Public Float

54.73M

Beta

0.88

Rev. Per Employee

N/A

P/E Ratio

38.05

EPS

$1.96

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

809.40K

 

LIVN Performance

1 Week
 
-1.95%
 
1 Month
 
0.70%
 
3 Months
 
13.35%
 
1 Year
 
57.48%
 
5 Years
 
-9.64%
 

LIVN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 11
Full Ratings ➔

About livanova plc - LIVN

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the following segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support (ACS). The Cardiopulmonary segment is involved in the design, development, manufacture, marketing and selling of cardiopulmonary products. The Neuromodulation segment is associated in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating DRE and DTD. The ACS segment deals with the design, development, manufacture, marketing and selling of temporary life support products. The company was founded in 1987 and is headquartered in London, the United Kingdom.

LIVN At a Glance

LivaNova Plc
20 Eastbourne Terrace
London, Greater London W2 6LG
Phone 44-203-325-0660 Revenue 1.39B
Industry Medical Specialties Net Income -242,471,000.00
Sector Health Technology 2025 Sales Growth 10.74%
Fiscal Year-end 12 / 2026 Employees 3,300
View SEC Filings

LIVN Valuation

P/E Current 38.055
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.418
Price to Book Ratio 2.802
Price to Cash Flow Ratio 13.20
Enterprise Value to EBITDA 11.078
Enterprise Value to Sales 2.273
Total Debt to Enterprise Value 0.138

LIVN Efficiency

Revenue/Employee 420,622.121
Income Per Employee -73,476.061
Receivables Turnover 6.427
Total Asset Turnover 0.543

LIVN Liquidity

Current Ratio 1.363
Quick Ratio 1.159
Cash Ratio 0.787

LIVN Profitability

Gross Margin 68.014
Operating Margin 16.219
Pretax Margin -15.906
Net Margin -17.468
Return on Assets -9.486
Return on Equity -19.242
Return on Total Capital -14.841
Return on Invested Capital -13.842

LIVN Capital Structure

Total Debt to Total Equity 36.148
Total Debt to Total Capital 26.551
Total Debt to Total Assets 16.645
Long-Term Debt to Equity 32.793
Long-Term Debt to Total Capital 24.086
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Livanova Plc - LIVN

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
1.02B 1.15B 1.25B 1.39B
Sales Growth
-1.31% +12.89% +8.66% +10.74%
Cost of Goods Sold (COGS) incl D&A
304.08M 368.10M 381.26M 443.98M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
57.80M 60.86M 51.14M 59.63M
Depreciation
32.60M 35.38M 33.93M 41.93M
Amortization of Intangibles
25.20M 25.47M 17.21M 17.70M
COGS Growth
-7.52% +21.05% +3.58% +16.45%
Gross Income
717.73M 785.45M 872.17M 944.07M
Gross Income Growth
+1.58% +9.44% +11.04% +8.24%
Gross Profit Margin
+70.24% +68.09% +69.58% +68.01%
2022 2023 2024 2025 5-year trend
SG&A Expense
595.40M 684.15M 687.09M 730.98M
Research & Development
136.42M 166.02M 180.51M 182.16M
Other SG&A
458.98M 518.13M 506.58M 548.81M
SGA Growth
-7.13% +14.90% +0.43% +6.39%
Other Operating Expense
616.00K 2.35M 19.64M (12.03M)
Unusual Expense
145.01M 144.54M 40.35M 417.65M
EBIT after Unusual Expense
(23.30M) (45.59M) 125.09M (192.53M)
Non Operating Income/Expense
(3.65M) 23.75M 26.29M 21.03M
Non-Operating Interest Income
4.70M 22.01M 30.07M 18.98M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
48.20M 59.39M 63.07M 49.29M
Interest Expense Growth
-3.89% +23.21% +6.20% -21.86%
Gross Interest Expense
48.20M 59.39M 63.07M 49.29M
Interest Capitalized
- - - -
-
Pretax Income
(75.14M) (81.23M) 88.31M (220.78M)
Pretax Income Growth
+39.63% -8.10% +208.72% -350.01%
Pretax Margin
-7.35% -7.04% +7.05% -15.91%
Income Tax
11.05M (98.88M) 25.06M 21.64M
Income Tax - Current - Domestic
4.86M 4.60M 4.41M 2.14M
Income Tax - Current - Foreign
4.78M 10.95M 13.85M 19.04M
Income Tax - Deferred - Domestic
- - 808.00K 5.09M
-
Income Tax - Deferred - Foreign
1.41M (114.43M) 5.99M (4.63M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(86.25M) 17.55M 63.23M (242.47M)
Minority Interest Expense
- - - -
-
Net Income
(86.25M) 17.55M 63.23M (242.47M)
Net Income Growth
+36.50% +120.34% +260.39% -483.45%
Net Margin Growth
-8.44% +1.52% +5.04% -17.47%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(86.25M) 17.55M 63.23M (242.47M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(86.25M) 17.55M 63.23M (242.47M)
EPS (Basic)
-1.6129 0.3253 1.1658 -4.4451
EPS (Basic) Growth
+39.87% +120.17% +258.38% -481.29%
Basic Shares Outstanding
53.47M 53.94M 54.24M 54.55M
EPS (Diluted)
-1.6129 0.3237 1.1587 -4.4451
EPS (Diluted) Growth
+39.87% +120.07% +257.95% -483.63%
Diluted Shares Outstanding
53.47M 54.21M 54.57M 54.55M
EBITDA
179.51M 159.81M 216.58M 284.76M
EBITDA Growth
+36.36% -10.97% +35.53% +31.48%
EBITDA Margin
+17.57% +13.85% +17.28% +20.51%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 81.50
Number of Ratings 11 Current Quarters Estimate 1.091
FY Report Date 06 / 2026 Current Year's Estimate 4.249
Last Quarter’s Earnings 0.98 Median PE on CY Estimate N/A
Year Ago Earnings 3.90 Next Fiscal Year Estimate 4.631
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 9 9 9 9
Mean Estimate 1.09 1.08 4.25 4.63
High Estimates 1.13 1.13 4.26 4.93
Low Estimate 1.06 1.03 4.23 4.49
Coefficient of Variance 1.91 3.23 0.25 3.08

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 7 7
OVERWEIGHT 1 1 1
HOLD 3 3 3
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Livanova Plc - LIVN

Date Name Shares Transaction Value
Sep 18, 2025 Donald J. Zurbay Director 2,560 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 18, 2025 Franco Poletti President, Cardiopulmonary 8,576 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Sep 18, 2025 Franco Poletti President, Cardiopulmonary 8,299 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $55.43 per share 460,013.57
Sep 18, 2025 Franco Poletti President, Cardiopulmonary 1,932 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Livanova Plc in the News